This program aims to equip primary care professionals with the skills to manage type 2 diabetes more effectively, particularly those who may be hesitant to prescribe glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It focuses on applying motivational interviewing techniques to engage patients, developing personalized strategies, and improving medication adherence. The program also emphasizes the use of the latest diabetes management guidelines and therapies, specifically GLP-1 RAs, to lower A1C levels and reduce hypoglycemia risk. It encourages understanding their mechanism of action, dosing optimization, administration, glycemic and extra-glycemic effects, safety, tolerability, and place in therapy. Additionally, it guides professionals to develop efficient clinic workflows and communication skills and to identify and overcome barriers contributing to therapeutic inertia and medication reluctance through patient-centered communication and decision-making processes.
10/31/2024
10/31/2025
Upon completion of the educational activity, participants should be better able to:
- Apply motivational interview techniques to effectively engage patients in their diabetes management, develop and implement personalized educational strategies tailored to individual patient needs, and utilize various methods to monitor and improve medication adherence among patients with type 2 diabetes.
- Employ the latest diabetes management guidelines, algorithms, and therapies to increase awareness of the lower risk of hypoglycemia with the use of GLP-1 RAs to lower A1C and understand the mechanism of action, dosing optimization, and administration, glycemic and extra-glycemic effects, safety and tolerability information, and place in therapy.
- Develop and implement efficient clinic workflows and communication skills to enhance diabetes care and patient management.
- Identify and overcome barriers contributing to therapeutic inertia and medication reluctance through patient-centered communication and decision-making processes.
The intended target audience for this program is U.S. primary care professionals who treat patients with T2D, particularly physicians, nurse practitioners, and physician assistants.
Physicians and Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AACE and AANP. AACE is accredited by the ACCME to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.
Please allow two weeks for MOC points to appear in your account on the ABIM website. Participation information will be shared.
Nurses
This activity is approved for 1.5 contact hours of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24106961. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American College of Endocrinology DBA American Association of Clinical Endocrinology (AACE) is approved by the California Board of Registered Nursing, Provider Number 17762, is eligible for up to 1.5 contact hours.
The American Association of Clinical Endocrinology (AACE) remains strongly committed to providing the best available evidence based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflicts of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflicts of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners and faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Planner/Faculty Disclosures
Amy Ogunsunlade – No relationships to disclose
Diane Alberson, MEd, CAE – No relationships to disclose
Michele McKay, MSN, APRN, FNP-C – No relationships to disclose
Dan O’Sullican – No relationships to disclose
Gordon Barker – No relationships to disclose
Katlyn Diamond, DNP, APRN, ANP-BC, CDES, BC-ADM – No relationships to disclose
Debbie Hinnen, APN, BC-ADM, CDES, FADCES, FAAN - Speakers’ Bureau - Lilly, Novo Nordisk, Intuity, Sanofi, Theracos Bio, Consultant – Novo Nordisk
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP - Speakers’ Bureau – Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, Cequr, Sanofi, Consultant – Lilly, Sanofi, Medtronic, Lifescan, Sequel, Sanofi
Inderpreet Madahar, MD - Stock Ownership – Lilly, Novo Nordisk
This activity is supported by an educational grant from Novo Nordisk Inc.